학술논문
EE514 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
Document Type
Abstract
Source
In Value in Health June 2023 26(6) Supplement:S153-S153
Subject
Language
ISSN
1098-3015